12:00 AM
 | 
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

La Jolla Pharmaceutical preclinical data

In a mouse model of NASH, oral LJPC-1010 significantly reduced non-alcoholic fatty liver disease (NAFLD) activity score vs. vehicle-treated controls (p<0.001). Additionally, LJPC-1010 led...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >